Boundless Bio, INC 10-Q quarterly reports

Boundless Bio announces a merger with Serapha Bio, Inc., shifting focus to Serapha's Alpha-1 Antitrypsin Deficiency therapy and discontinuing its own ecDTx programs, while reporting increased net loss and significant workforce reduction.

Boundless Bio reports Q1 2026 results, detailing a net loss of $13.6 million, a strategic focus on BBI-940, and a significant lease termination and restructuring.

Boundless Bio reports reduced net losses and extended cash runway into H1 2028, driven by strategic portfolio prioritization and workforce reduction.

Boundless Bio, Inc. reported Q2 2025 results, revealing a strategic pipeline prioritization, workforce reduction, and an extended cash runway into the first half of 2028.

Boundless Bio, a clinical-stage oncology company, details its Q1 2025 financial results, highlighting ongoing research and development efforts in ecDNA-directed therapeutics.

Boundless Bio reported its Q3 2024 financial results, highlighting progress in its clinical programs and providing an update on its financial position, including a cash runway into the fourth quarter of 2026.

Boundless Bio, a clinical-stage oncology company, reported its second quarter 2024 financial results, highlighting progress in its clinical trials and a strategic shift to extend its cash runway.

Boundless Bio, a clinical-stage oncology company, reported a net loss of $15.4 million for the first quarter of 2024, while highlighting progress in its clinical programs and platform development.